DDL 2026 - Intertek at the Drug Delivery to the Lungs Conference

We are excited to be DDL2026 Platinum Sponsors again at this International Conference. Discuss your respiratory drug delivery challenges for all categories of inhaled or nasal products, including dry powder formulations and devices, nebulized solutions/suspensions, metered dose inhaler products and a range of novel respiratory delivery systems.
Our team of experts will be available at our booth to discuss how we support development projects for both small and large molecules across all respiratory delivery technology platforms. Get in touch now to arrange a meeting. Key themes for DDL2026 discussions include:

• Formulation development - including particle engineering approaches
• Specialist support for biologics and DNA based medicines with a dedicated suite for testing and characterisation
• Independent device screening and selection
• Clinical manufacturing
• CMC package support
• ICH stability study testing and program management
• QC and GMP Batch Release testing
• In-vitro bioequivalence (IV-BE) studies including
  GMP IV-IVC tools; MDRS, Inhaled Dissolution, Idealised inlet models and realistic breathing profiles for impaction testing

Missed our DDL 2025 CONFERENCE POSTERS?

You can request our scientific posters that showcase research and innovation in inhaled and nasal drug development.

1.    Product vs Human Factors - Assessment of Automated and Manual Shaking Parameters on Through Life Dose Performance of Symbicort pMDI
Thomas Moody1, Mark Parry1, Josh Rigby1, Abbey Grahame1, Justyna Kinga Powroznik1, Renz Rabe1 & Jamie Clayton2
1Intertek Melbourn, Saxon Way, Melbourn SG8 6DN, UK
2Copley Scientific Limited, Colwick Quays Business Park, Road No. 2, Nottingham, NG4 2JY, UK

2.    Development and Characterisation of a Semaglutide Nasal Drug Product 
Sylvester Olusoji1, Mark Parry1, Alain Regard2
1Intertek Melbourn, Saxon Way, Melbourn, SG8 6DN, UK
2Nemera la Verpillière, 63 Avenue Tony Garnier, 69007 Lyon, France

3.    Analytical Considerations for Nitrosamine Formation when Formulating pMDI’s with Next-Generation Low GWP Propellant Systems
John McLaughlin1, Mark Parry1 & Miles Jeanneret1
1Intertek Melbourn, Saxon Way, Melbourn, Herts, SG8 6DN, UK

These posters highlight key developments in formulation science, device performance, and analytical strategies for inhaled and nasal drug products. Request your poster copies today, and we'll be happy to send them to you after the event.

OUR OINDP DEVELOPMENT EXPERTISE
With over 35 years of experience in supporting our clients’ inhaled and nasal product developments, we deliver world-class support to help you meet the challenges of your demanding development programs. We provide integrated OINDP development and testing services for both small molecules and biologics through its centres of excellence across Europe. We conduct critical performance and quality testing such as laser particle sizing, aerodynamic particle size distribution (APSD) by impaction (ACI, NGI) and spray pattern/plume geometry. Intertek’s integrated formulation and analytical teams carry out early stage pre-formulation support, solubility screening, drug-excipient compatibility, stability testing and device selection support. For large molecule development, comprehensive protein characterisation services supported by forced degradation and stability monitoring for the protein’s structure and bioactivity throughout formulation and storage can also be provided. Interaction with the device and closure systems are evaluated through comprehensive extractable and leachable testing and toxicological assessments. The laboratory is inspected and approved by the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for GMP compliance. The laboratory has also been inspected by the US Food and Drug Administration (FDA) against GMP as part of clients’ pre-approval inspections. 

• BROCHURE: Our Orally Inhaled and Nasal Drug Product Development Expertise
• WEBINAR RECORDING: Development of Inhaled Oligo or mRNA Therapeutics
• ARTICLE: IVBE Particle Characterisation of Generic Mometasone Furoate using MDRS and Laser Diffraction